COVID-19 Drug Development
COVID-19 drug development is a research process to discover a preventative and therapeutic prescription of drugs that would control the severity of coronavirus disease. From 2020 to 2021, various drug companies, biotechnology firms, university research groups, and health organizations were started developing over 600 potential therapies for corona virus disease with various stages of preclinical or clinical research, with 391 therapeutic candidates in clinical trials, as of January 2021.
Committee Members
Sergey Suchkov
Sechenov University and Moscow Engineering Physical Institute, Russian Federation
Marino Nebuloni
Parma University, Italy
Esmaiel Jabbari
University of South Carolina, United States
Paul Millner
University of Leeds, United Kingdom PDDS 2021 Speakers
Jan Versijpt
University Hospital Brussels, Belgium
Madhav Bhatia
University of Otago, New Zealand
Stefanie Santos
University Hospital Zurich, Switzerland
Dmitry Ustyuzhanin
National Medical Research Center of Cardiology, Russian Federation
Anna Caprifico
Kingston University, United Kingdom
Annalisa Dalmoro
University of Salerno, ItalySubmit your abstract Today
Title : Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease.
Metin Basaranoglu, Istanbul University, Turkey
Title : Drug Delivery to Stem Cells in Regenerative Medicine
Esmaiel Jabbari, University of South Carolina, United States
Title : Strategy in crystallization process to ensure solid state stability of drug substance
Marino Nebuloni , Parma University, Italy
Title : Personalized and Precision Medicine (PPM) as a Unique Healthcare Model to Be Set Up via Biodesign and Translational Applications and Upgraded Business Modeling to Secure the Human Healthcare, Wellness and Biosafety
Sergey Suchkov , Sechenov University and Moscow Engineering Physical Institute, Russian Federation
Title : Targeted nanoparticles for diagnostic and theranostic applications
Paul Millner, University of Leeds, United Kingdom
Title : Nanostructured Formulations in Skin Cancer: Challenges and Perspectives
Daniela Monti , University of Pisa, Italy
Title : Introducing the Sorush Cancer Treatment Protocol (SCTP)
Sorush Niknamian, Violet Cancer Institute, United States
Title : Effect of different hydrotropic agents on solubility and dissolution of famotidine
Hussien el messiry , National Organization of Drug Control and Research, Egypt
Title : In-vitro assessment of oil formulation & rat plasma stability of multiple pyrethroids using HPLC & LC-MS/MS based methods
Apoorva Sharma, Dr. K.N.Modi Institute of Pharmaceutical Education & Research, India
Title : Hydrogen Sulfide: A Stinky Gas….. and Novel Therapeutic Target for Inflammatory Disease
Madhav Bhatia , University of Otago, New Zealand